Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kritischer Rohstoff, strategische Wende: Warum diese Aktie jetzt auf das Radar kluger Investoren gehört
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A400EJ | ISIN: US45773H4092 | Ticker-Symbol: GBM
Tradegate
28.03.25
16:02 Uhr
1,550 Euro
-0,050
-3,12 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INOVIO PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
INOVIO PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5601,62028.03.
1,5801,61028.03.

Aktuelle News zur INOVIO PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INOVIO PHARMACEUTICALS Aktie jetzt für 0€ handeln
19.03.Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues12
19.03.Inovio stock price target cut to $12 by Citizens JMP26
18.03.INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights151Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)...
► Artikel lesen
18.03.Inovio Pharmaceuticals Inc. Q4 Income Declines359WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) released a profit for fourth quarter that decreased from last yearThe company's bottom line came in at $19.4 million, or $0.65 per share....
► Artikel lesen
18.03.INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report2
18.03.INOVIO PHARMACEUTICALS, INC. - 10-K, Annual Report3
17.03.Inovio Pharmaceuticals Q4 2024 Earnings Preview4
14.03.Inovio stock holds firm with $18 target from JMP Securities12
14.03.INOVIO Announces Promising Interim Results From Phase 1 Proof-of-Concept Trial Of DMAbs For COVID-19459LONDON (dpa-AFX) - INOVIO (INO) announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DNA-Encoded Monoclonal Antibodies or DMAbs for COVID-19.In the trial...
► Artikel lesen
14.03.INOVIO Pharmaceuticals, Inc.: INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-1977Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies...
► Artikel lesen
12.02.Inovio respiratory DNA drug candidate shows promise in early trial12
12.02.INO-3107 zeigt vielversprechende Ergebnisse bei der Reduzierung von Operationen für RRP-Patienten20
12.02.INOVIO Pharmaceuticals, Inc.: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications202Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by...
► Artikel lesen
08.01.What's Going On With Inovio Pharmaceuticals (INO) Stock?20
07.01.Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing33
16.12.24INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report40
13.12.24Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet26
13.12.24Why Inovio Pharmaceuticals (INO) Stock Is Down 40%33
13.12.24Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen880OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93. iSpecimen...
► Artikel lesen
13.12.24Inovio Pharmaceuticals Prices $30 Mln Public Offering With Warrants714WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants...
► Artikel lesen
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1